NUGX
Sign in
NuGenerex Immuno-Oncology, Inc.
Save
10.03K
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
NuGenerex Immuno-Oncology, Inc., an oncology company, focuses on the modulation of the immune system to treat cancer. The company is developing immunotherapeutic products and vaccines. It is developing AE37, a peptide immunotherapeutic vaccine, which is in Phase II clinical trials for the treatment of metastatic triple negative breast cancer.
Similar securities
Based on sector and market capitalization
Report issue